The FDA didn’t routinely test the medications for quality problems or use its vast repository of drug-related complaints to proactively track whether they were harming the people who relied on them.

From June 8 to June 12, thousands of middle and high school students from across the United States and around the world will gather at the University of Maryland for the National History Day contest.

The information about LUMRYZ’s Orphan Drug Designation and its development status is based on a press release statement from Avadel Pharmaceuticals. In other recent news, Avadel Pharmaceuticals has ...

Neurizon (ASX:NUZ) has officially snagged a U.S. patent for its neurodegenerative disease and cancer drug candidate NUZ-001, designated orphan status by the FDA last year. The microcap stock ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ ...

The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from sufficient to maintain momentum in the rare disease space.

Nexus Pharmaceuticals shared that on May 9, 2025, it won a patent litigation involving injectable cyclophosphamide, a drug that has been approved for certain kinds of cancer. Nexus had been ...

Novo Nordisk is locked in a patent infringement battle with Dr Reddy’s Laboratories and OneSource Specialty Pharma For a better experience, Read this story in our App Companies ...

"This patent is a strategic milestone for Renovaro,” said David Weinstein, CEO of Renovaro. "Together with our previously granted patent, it forms the technological foundation of a scalable, ...